What is the purpose of this trial?
This study is to determine first, the recommended Phase 2 dose of NKTR-214 when administered in combination with nivolumab, and then, the clinical benefit, safety, and tolerability of combining NKTR-214 with nivolumab in select patients with melanoma, renal cell carcinoma or non-small cell lung cancer. Both drugs target the immune system and may act synergistically to promote anti-cancer effects.
Start Date: 05/09/2017
End Date: 06/30/2020
Last Updated: 02/14/2019
Study HIC#: 1609018350